Related references
Note: Only part of the references are listed.Regulation of Bax-dependent apoptosis by mitochondrial deubiquitinase USP30
Ding Yan et al.
CELL DEATH DISCOVERY (2021)
Note of Caution for the Aqueous Behaviour of Metal-Based Drug Candidates
Anna Notaro et al.
CHEMMEDCHEM (2020)
Population-based meta-analysis of bortezomib exposure-response relationships in multiple myeloma patients
Li Zhang et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2020)
Broad Spectrum Deubiquitinase Inhibition Induces Both Apoptosis and Ferroptosis in Cancer Cells
Li Yang et al.
FRONTIERS IN ONCOLOGY (2020)
Synthesis and biological evaluation of quercetin-zinc (II) complex for anti-cancer and anti-metastasis of human bladder cancer cells
Yu-Hsiang Lee et al.
IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL (2019)
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib
Min Jae Lee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
Pawel Robak et al.
DRUGS IN R&D (2019)
A new gold(I) complex-Au(PPh3)PT is a deubiquitinase inhibitor and inhibits tumor growth
Xiaofen Li et al.
EBIOMEDICINE (2019)
Inhibition of Proteasomal Deubiquitinase by Silver Complex Induces Apoptosis in Non-Small Cell Lung Cancer Cells
Xin Chen et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase
Xin Chen et al.
BIOMETALS (2018)
Proteasome Structure and Assembly
Lauren Budenholzer et al.
JOURNAL OF MOLECULAR BIOLOGY (2017)
In Vivo Ubiquitin Linkage-type Analysis Reveals that the Cdc48-Rad23/Dsk2 Axis Contributes to K48-Linked Chain Specificity of the Proteasome
Hikaru Tsuchiya et al.
MOLECULAR CELL (2017)
Proteasome inhibitors in cancer therapy
Elisabet E. Manasanch et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases
Chong Zhao et al.
ONCOTARGET (2017)
Multiple Myeloma Cell Drug Responses Differ in Thermoplastic vs PDMS Microfluidic Devices
Thomas A. Moore et al.
ANALYTICAL CHEMISTRY (2017)
Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy
Chong Zhao et al.
BIOCHEMICAL PHARMACOLOGY (2016)
Cupriphilic compounds to aid in proteasome inhibition
Sreya Mukherjee et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
Xiaoying Lan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?
Karthik Selvaraju et al.
DRUG RESISTANCE UPDATES (2015)
Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms
Xin Chen et al.
ONCOTARGET (2014)
A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases
Ningning Liu et al.
SCIENTIFIC REPORTS (2014)
MG132, a proteasome inhibitor, induces apoptosis in tumor cells
Na Guo et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2013)
The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma
Chiara Pautasso et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Proteasome deubiquitinases as novel targets for cancer therapy
Padraig D'Arcy et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2012)
Metal complexes as inhibitors of the 26S proteasome in tumor cells
Claudio N. Verani
JOURNAL OF INORGANIC BIOCHEMISTRY (2012)
Anticancer Activity of Metal Complexes: Involvement of Redox Processes
Ute Jungwirth et al.
ANTIOXIDANTS & REDOX SIGNALING (2011)
Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
D. Chen et al.
CURRENT CANCER DRUG TARGETS (2011)
Inhibition of proteasome deubiquitinating activity as a new cancer therapy
Padraig D'Arcy et al.
NATURE MEDICINE (2011)
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
Francesco Parlati et al.
BLOOD (2009)
Quantitative Proteomics Reveals the Function of Unconventional Ubiquitin Chains in Proteasomal Degradation
Ping Xu et al.
CELL (2009)
Point mutation of the proteasome β5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line
Shuqing Lu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Relative structural and functional roles of multiple deubiquitylating proteins associated with mammalian 26S proteasome
Elena Koulich et al.
MOLECULAR BIOLOGY OF THE CELL (2008)
Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate
AF Kisselev et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Alzheimer's associated variant ubiquitin causes inhibition of the 26S proteasome and chaperone expression
AD Hope et al.
JOURNAL OF NEUROCHEMISTRY (2003)
Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression
BY Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
